Data from a late-stage study shows that transfusion-dependent thalassemia patients who received Agios' (AGIO) Pyrukynd demonstrated a statistically significant reduction in transfusion burden.
Here is how Arcutis Biotherapeutics, Inc. (ARQT) and Canopy Growth Corporation (CGC) have performed compared to their sector so far this year.
Data from a late-stage study shows that treatment with J&J's (JNJ) experimental drug met all study endpoints in depression patients with insomnia symptoms.